Imara Overview

  • Founded
  • 2016

Founded
  • Status
  • Public

  • Employees
  • 41

Employees
  • Stock Symbol
  • IMRA

Stock Symbol
  • Investments
  • 2

  • Share Price
  • $1.14

  • (As of Friday Closing)

Imara General Information

Description

Imara Inc is a clinical-stage biopharmaceutical company engaged in developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Its lead product candidate, tovinontrine (IMR-687), is an oral, highly selective, potent small-molecule inhibitor of phosphodiesterase-9, or PDE9.

Contact Information

Website
www.imaratx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 116 Huntington Avenue
  • 6th Floor
  • Boston, MA 02116
  • United States
+1 (617) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Imara Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.14 $1.16 $0.97 - $5.10 $30.5M 26.3M 59.4K -$2.07

Imara Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV (38,369) (43,003) 287,745
Revenue 0 0 0 0
EBITDA (53,787) (51,517) (41,743) (24,008)
Net Income (54,054) (51,384) (41,360) (23,463)
Total Assets 64,666 93,646 90,842 33,298
Total Debt 445 652 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Imara Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Imara‘s full profile, request access.

Request a free trial

Imara Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Imara‘s full profile, request access.

Request a free trial

Imara Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Imara Inc is a clinical-stage biopharmaceutical company engaged in developing and commercializing novel therapeutics to
Biotechnology
Boston, MA
41 As of 2021
00000
0000 0000-00-00
00000000 00000

000000

lla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mol
0000000000000
New York, NY
00 As of 0000
00000
0000 0000-00-00
000000&0 00000

0000 0

ate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proiden
0000 000000000
Larnaca, Cyprus
00 As of 0000
00.000
0000000000 0 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Imara Competitors (63)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Prevail Therapeutics Formerly VC-backed New York, NY 00 00000 000000&0 00000
0000 000000000000 Venture Capital-Backed Larnaca, Cyprus 00 00.000 0000000000 0 00.000
0000000000 0000000 Formerly VC-backed Novato, CA 0000 00000 000000000 00000
000000000 00000000 Venture Capital-Backed Rockville, MD 0 000.00 0000000000 0 000.00
00000 000000000 Formerly VC-backed Boulder, CO 000 00000 000000&0 00000
You’re viewing 5 of 63 competitors. Get the full list »

Imara Patents

Imara Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3965768-A1 Pde9 inhibitors for treating thalassemia Pending 07-May-2019 00000000000
AU-2020267475-A1 Pde9 inhibitors for treating thalassemia Pending 07-May-2019 00000000000
US-20220047589-A1 Pde9 inhibitors for treating thalassemia Abandoned 07-May-2019 00000000000
EP-3946348-A1 Pde9 inhibitors for treating sickle cell disease Pending 05-Apr-2019 000000000
US-20220023302-A1 Pde9 inhibitors for treating sickle cell disease Abandoned 05-Apr-2019 A61K45/06
To view Imara’s complete patent history, request access »

Imara Executive Team (8)

Name Title Board Seat Contact Info
Rahul Ballal Ph.D Chief Executive Officer & Board Member
Michael Gray Chief Financial Officer & Chief Operating Officer
Michael Gray Chief Financial Officer, Finance & Chief Operating Officer, Operations
You’re viewing 3 of 8 executive team members. Get the full list »

Imara Board Members (19)

Name Representing Role Since
Barbara Dalton Ph.D Self Board Member 000 0000
Carl Goldfischer MD Bay City Capital Board Member 000 0000
David Bonita MD Self Board Member 000 0000
David Mott Self Chairman & Board Member 000 0000
Edward Conner MD Imara Board Member 000 0000
You’re viewing 5 of 19 board members. Get the full list »

Imara Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Imara Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Imara‘s full profile, request access.

Request a free trial

Imara Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 (000 04-Nov-2021 000000000 Buildings and Property 00000 000
Lundbeck (Exclusive Worldwide License To IMR-687, A Hemoglobinopathy Drug) 16-Apr-2016 Corporate Asset Purchase Buildings and Property
To view Imara’s complete investments history, request access »